Physitrack Limited (SE:PTRK)
:PTRK
Want to see SE:PTRK full AI Analyst Report?
Top Page
Physitrack Limited
(PTRK)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr8.00
▼(-39.16% Downside)
Action:Reiterated
Date:04/26/26
The score is held back primarily by weak and volatile profitability (deeply negative TTM net margin) and bearish technical trends (price below key moving averages with negative MACD). These are partially offset by comparatively strong cash generation and manageable leverage, but valuation is constrained by the negative P/E and lack of dividend yield data.
Positive Factors
Cash generation & free cash flow growth
Sustained positive operating and free cash flow with double-digit FCF growth provides durable internal funding for product development, customer success, and working-capital needs. Over 2–6 months this reduces reliance on external financing and supports operational continuity despite earnings volatility.
Negative Factors
Deeply negative net margin and volatile profitability
A large net loss erodes shareholder value and constrains reinvestment capacity. The disconnect between strong EBITDA and deep net loss implies interest, tax, depreciation, or one-off items are materially depressing net results, making earnings recovery and consistent profitability uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation & free cash flow growth
Sustained positive operating and free cash flow with double-digit FCF growth provides durable internal funding for product development, customer success, and working-capital needs. Over 2–6 months this reduces reliance on external financing and supports operational continuity despite earnings volatility.
Read all positive factors
Physitrack Limited (PTRK) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr134.96M
Dividend YieldN/A
Average Volume (3M)49.62K
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue Growth-17.28%
EPS Growth-13.86%
CountrySE
Employees81
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.52
Shares Outstanding16,260,765
10 Day Avg. Volume41,844
30 Day Avg. Volume49,617
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)1.97
Price to Sales (P/S)1.42
P/FCF Ratio5.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr13.80M
Physitrack Limited Business Overview & Revenue Model
Company Description
Physitrack PLC, together with its subsidiaries, operates as a digital healthcare provider worldwide. It offers SaaS platform, a cloud-based software platform used by single practitioners and large healthcare organizations, which enables the digita...
How the Company Makes Money
Physitrack Limited primarily makes money by selling subscription access to its rehabilitation software platform to healthcare professionals and organizations. Revenue is typically generated through recurring fees paid by individual clinicians, cli...
Physitrack Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.50M | 13.77M | 16.18M | 15.18M | 12.51M | 7.81M |
| Gross Profit | 3.87M | 518.13K | 16.18M | 3.87M | 12.37M | 7.81M |
| EBITDA | 3.23M | 518.13K | -2.09M | 7.09M | 2.57M | 1.07M |
| Net Income | -8.41M | -6.92M | -6.45M | 3.20M | 92.32K | -815.03K |
Balance Sheet | ||||||
| Total Assets | 18.70M | 19.15M | 30.51M | 38.70M | 41.31M | 32.28M |
| Cash, Cash Equivalents and Short-Term Investments | 435.91K | 654.30K | 723.39K | 536.03K | 577.74K | 13.32M |
| Total Debt | 3.98M | 3.93M | 4.81M | 3.58M | 831.66K | 1.31K |
| Total Liabilities | 8.74M | 9.16M | 11.34M | 13.13M | 18.94M | 3.63M |
| Stockholders Equity | 9.96M | 9.95M | 19.17M | 25.57M | 22.37M | 23.29M |
Cash Flow | ||||||
| Free Cash Flow | 2.40M | 3.85M | -363.54K | -773.78K | -3.04M | 654.05K |
| Operating Cash Flow | 3.84M | 3.88M | 3.13M | 2.65M | 1.45M | 659.81K |
| Investing Cash Flow | -3.33M | -3.21M | -3.49M | -5.04M | -14.78M | -4.54M |
| Financing Cash Flow | -361.29K | -726.55K | 537.79K | 2.34M | 795.50K | 14.85M |
Physitrack Limited Technical Analysis
Neutral
13.15
Price Trends
8.49
Negative
9.42
Negative
12.77
Negative
Market Momentum
-0.19
Negative
55.92
Neutral
40.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PTRK, the sentiment is Neutral. The current price of 13.15 is above the 20-day moving average (MA) of 7.86, above the 50-day MA of 8.49, and above the 200-day MA of 12.77, indicating a neutral trend. The MACD of -0.19 indicates Negative momentum. The RSI at 55.92 is Neutral, neither overbought nor oversold. The STOCH value of 40.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:PTRK.
Physitrack Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr49.88M | -38.58 | -4.02% | ― | -0.94% | -656.06% | |
49 Neutral | kr134.96M | -1.47 | ― | ― | -17.28% | -13.86% | |
49 Neutral | kr231.72M | -3.66 | -51.35% | ― | ― | 9.40% | |
44 Neutral | kr28.03M | -3.61 | 209.66% | ― | -4.19% | 27.20% | |
44 Neutral | kr176.75M | -509.36 | -1291.15% | ― | ― | 49.74% | |
41 Neutral | kr376.14M | -2.24 | -108.15% | ― | 106.74% | 89.96% |
* Healthcare Sector Average
SE:PTRK
Physitrack Limited
8.30
-5.85
-41.34%
SE:AINO
Aino Health AB
0.14
-0.21
-61.08%
SE:ISOFOL
Isofol Medical AB
0.72
-0.28
-28.06%
SE:QLINEA
Q-linea AB
20.20
-21.82
-51.92%
SE:KONT
Kontigo Care AB
1.42
-0.65
-31.31%
SE:ACTI
Active Biotech AB
6.71
-10.24
-60.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.